“We would like exploration to open the door to new developments, so we aim to make the necessary regulatory changes to increase legal certainty for those who are willing to invest in exploration.”
MANAGING DIRECTOR, MITSUI CHEMICALS ASIA PACIFIC (MCAP)
"MCAP is committed to continue our support to Mitsui Chemicals Group in moving towards a solution-based business model to respond to social and environmental challenges."
PRESIDENT AND CEO & CHIEF SCIENTIFIC OFFICER, VYANT BIO
"At Vyant Bio we are reinventing how drugs are discovered for complex neurological and neurodegenerative disorders by applying a human-first approach."
"AC Immune is combining diagnostics and therapeutics, and it has developed the tools to enable detection and clearance of specific pathological proteins underlying neurodegenerative diseases."
"Digital platforms for industrial chemicals are becoming more and more important as the world embraces digital engagement in every sphere of our life."
PRESIDENT, AMPAC FINE CHEMICALS, AN SK PHARMTECO COMPANY
"Outside of our manufacturing capabilities, AFC is investing and featuring AMPAC Analytical given the growing demand for pharmaceutical testing services."
MACIG 2025 - Mining in Africa Country Investment Guide
It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.